ALNY
Alnylam Pharmaceuticals Inc.
$295.50
-$1.95(-0.66%)
35
Overall
20
Value
20
Tech
65
Quality
Market Cap
$59.82B
Volume
649.71K
52W Range
$284.28 - $495.55
Target Price
$446.44
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $47.2M | $89.9M | $74.9M | $219.8M | $854.4M | $1.5B | $1.0B | $1.8B | $2.2B | $3.7B | ||
| Total Revenue | $47.2M | $89.9M | $74.9M | $219.8M | $492.9M | $844.3M | $1.0B | $1.8B | $2.2B | $3.7B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $590.0M | $1.8M | $25.1M | $74.2M | $140.1M | $168.8M | $268.2M | $306.5M | $677.2M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $47.2M | $89.9M | $73.1M | $194.7M | $418.7M | $704.1M | $868.6M | $1.6B | $1.9B | $3.0B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $471.7M | $590.0M | $887.8M | $1.1B | $1.2B | $1.4B | $1.7B | $1.8B | $2.1B | $2.5B | ||
| Research & Development | $382.4M | $390.6M | $505.4M | $655.1M | $654.8M | $792.2M | $883.0M | $1.0B | $1.1B | $1.3B | ||
| Research Expense | $382.4M | $390.6M | $505.4M | $655.1M | $654.8M | $792.2M | $883.0M | $1.0B | $1.1B | $1.3B | ||
| Selling, General & Administrative | $89.4M | $199.4M | $382.4M | $479.0M | $588.4M | $620.6M | $770.7M | $795.6M | $975.5M | $1.2B | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | -- | $12.4M | $29.7M | -- | ||
| General & Administrative Expenses | $89.4M | $199.4M | $382.4M | $479.0M | $588.4M | $620.6M | $770.7M | $795.6M | $975.5M | $1.2B | ||
| Salaries & Wages | $75.5M | $92.8M | $157.8M | $3.4M | $571.0K | $3.3M | $230.6M | -- | -- | -- | ||
| Depreciation & Amortization | $9.6M | $11.9M | $12.8M | $16.6M | $30.2M | $36.8M | $39.1M | $51.6M | $55.1M | -- | ||
| Depreciation & Amortization | $9.6M | $11.9M | $12.8M | $16.6M | $30.2M | $36.8M | $39.1M | -- | -- | -- | ||
| Other Operating Expenses | $471.7M | $-590.0M | -- | $53.8M | $53.3M | $63.6M | $63.4M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-424.6M | $-500.1M | $-814.7M | $-939.4M | $-828.4M | $-708.7M | $-785.1M | $-282.2M | $-176.9M | $501.6M | ||
| EBITDA | $-395.0M | $-490.9M | $-760.7M | $-848.1M | $-696.7M | $-619.4M | $-929.9M | $-258.2M | $-178.8M | $631.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $84.5M | $143.0M | $156.0M | $121.2M | $141.9M | $252.6M | ||
| Intinc | -- | -- | -- | $33.4M | $11.8M | $1.6M | $24.8M | $95.6M | $122.0M | $111.5M | ||
| Net Non-Operating Interest Income/Expense | -- | $12.2M | -- | $33.4M | $-72.7M | $-143.0M | $131.2M | $-25.7M | $-19.9M | $-141.2M | ||
| Gain on Sale of Securities | $8.3M | $12.2M | $29.3M | $33.4M | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-14.5M | $-9.2M | $-33.4M | $-20.7M | $-45.5M | $471.0K | $-210.8M | $125.7M | $180.6M | $37.3M | ||
| Other Special Charges | $6.2M | $-3.0M | $4.2M | $20.7M | $45.5M | $-471.0K | $-210.8M | $-125.7M | $-180.6M | $-37.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | $20.6M | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-410.1M | $-490.9M | $-760.7M | $-885.3M | $-771.1M | $-709.1M | $-971.0M | $-312.3M | $-235.5M | $575.8M | ||
| Pre-Tax Income | $-410.1M | $-490.9M | $-760.7M | $-885.3M | $-855.6M | $-852.1M | $-1.1B | $-433.5M | $-377.4M | $323.2M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $823.0K | $863.0K | $2.7M | $680.0K | $4.2M | $6.7M | $-99.2M | $9.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $-410.1M | $-490.9M | $-761.5M | $-886.1M | $-858.3M | $-852.8M | $-1.1B | $-440.2M | $-278.2M | $313.7M | ||
| Net Income (Continuing Operations) | $-410.1M | $-490.9M | $-761.5M | $-886.1M | $-858.3M | $-852.8M | $-1.1B | $-440.2M | $-278.2M | $313.7M | ||
| Net Income (Discontinued Operations) | $-410.1M | $-490.9M | $-761.5M | $-886.1M | $-858.3M | $-852.8M | $-1.1B | $-440.2M | $-278.2M | $313.7M | ||
| Net Income (Common Stockholders) | $-410.1M | $-490.9M | $-761.5M | $-886.1M | $-489.0M | $-852.8M | $-1.1B | $-440.2M | $-278.2M | $313.7M | ||
| Normalized Income | $-266.6M | $-319.1M | $-621.5M | $-699.3M | $-675.9M | -- | -- | -- | -- | $319.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $471.7M | $1.2B | $889.6M | $1.2B | $1.3B | $1.5B | $1.8B | $2.1B | $2.4B | $3.2B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $85.6M | $90.6M | $100.6M | $109.3M | $115.0M | $118.5M | $121.7M | $124.9M | $127.7M | $131.0M | ||
| Average Shares Outstanding (Diluted) | $85.6M | $90.6M | $100.6M | $109.3M | $115.0M | $118.5M | $121.7M | $124.9M | $127.7M | $134.7M | ||
| Shares Outstanding | $86.0M | $99.9M | $106.3M | $112.6M | $117.0M | $133.5M | $124.1M | $125.9M | $129.5M | $132.6M | ||
| Basic EPS | $-4.79 | -- | $-7.57 | $-8.11 | $-7.46 | $-7.2 | $-9.3 | $-3.52 | $-2.18 | $2.39 | ||
| Basic EPS (Continuing Operations) | $-4.79 | -- | $-7.57 | $-8.11 | $-7.46 | $-7.2 | $-9.3 | $-3.52 | $-2.18 | $2.39 | ||
| Diluted EPS | $-4.79 | $-5.42 | $-7.57 | $-8.11 | $-7.46 | $-7.2 | $-9.3 | $-3.52 | $-2.18 | $2.33 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-7.2 | $-9.3 | $-3.52 | $-2.18 | $2.33 | ||
| OTHER METRICS | ||||||||||||
| Non Recurring Operation Expense | -- | -- | $-20.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $89.4M | $199.4M | $382.4M | $479.0M | $588.4M | $620.6M | $770.7M | $795.6M | $975.5M | $1.2B | ||
| Rent And Landing Fees | $15.9M | $18.7M | $40.6M | $52.4M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALNY | $295.50 | -0.7% | 649.71K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Alnylam Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW